+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 64 Pages
  • July 2021
  • GlobalData
  • ID: 1314899
Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co Ltd develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary products, food additives, chemical product materials, food ingredients, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd Key Recent Developments

May 12, 2021: Sumitomo Dainippon Pharma Notice of Change of Trade Name and Partial Amendment to Articles of Incorporation
Mar 05, 2021: Sumitomo Dainippon Pharma announces posting of Impairment Loss
Mar 04, 2021: Sumitomo Dainippon Pharma earns recognition for the first time in the health & productivity management stock selection
Mar 02, 2021: Sumitomo Dainippon Pharma announces organizational realignment and changes in the positions assumed by executive officers and other key positions
Feb 26, 2021: Sumitomo Dainippon Pharma announces changes of Representative Directors and Executive Officers

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Sumitomo Dainippon Pharma Co Ltd - Key Facts
  • Sumitomo Dainippon Pharma Co Ltd - Key Employees
  • Sumitomo Dainippon Pharma Co Ltd - Key Employee Biographies
  • Sumitomo Dainippon Pharma Co Ltd - Major Products and Services
  • Sumitomo Dainippon Pharma Co Ltd - History
  • Sumitomo Dainippon Pharma Co Ltd - Company Statement
  • Sumitomo Dainippon Pharma Co Ltd - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Sumitomo Dainippon Pharma Co Ltd - Business Description
  • Business Segment: Other Business
  • Overview
  • Performance
  • Business Segment: Pharmaceuticals Business
  • Overview
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: North America
  • Performance
  • Geographical Segment: Other Regions
  • Performance
  • R&D Overview
  • Sumitomo Dainippon Pharma Co Ltd - Corporate Strategy
  • Sumitomo Dainippon Pharma Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Sumitomo Dainippon Pharma Co Ltd - Strengths
  • Sumitomo Dainippon Pharma Co Ltd - Weaknesses
  • Sumitomo Dainippon Pharma Co Ltd - Opportunities
  • Sumitomo Dainippon Pharma Co Ltd - Threats
  • Sumitomo Dainippon Pharma Co Ltd - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • Mar 05, 2021: Sumitomo Dainippon Pharma announces posting of Impairment Loss
  • Mar 04, 2021: Sumitomo Dainippon Pharma earns recognition for the first time in the health & productivity management stock selection
  • Mar 02, 2021: Sumitomo Dainippon Pharma announces organizational realignment and changes in the positions assumed by executive officers and other key positions
  • Feb 26, 2021: Sumitomo Dainippon Pharma announces changes of Representative Directors and Executive Officers
  • Feb 01, 2021: Sumitomo Dainippon Pharma announces investment in a Venture Capital Fund
  • Jan 28, 2021: Sumitomo Dainippon Pharma: Summary of consolidated financial results for the third quarter of the year ending March 31, 2021
  • Oct 28, 2020: Sumitomo Dainippon Pharma announces financial results for the second quarter of the year ending March 31, 2021
  • Aug 05, 2020: Sumitomo Dainippon Pharma, Sompo Japan, and Aikomi announce collaboration on R&D and commercialization of digital devices for Dementia and Nursing Care
  • May 21, 2020: Sumitovant Biopharma's family of companies achieve multiple clinical and corporate milestones in the first full quarter of Sumitovant's operation

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher

List of Tables
  • Sumitomo Dainippon Pharma Co Ltd, Key Facts
  • Sumitomo Dainippon Pharma Co Ltd, Key Employees
  • Sumitomo Dainippon Pharma Co Ltd, Key Employee Biographies
  • Sumitomo Dainippon Pharma Co Ltd, Major Products and Services
  • Sumitomo Dainippon Pharma Co Ltd, History
  • Sumitomo Dainippon Pharma Co Ltd, Other Locations
  • Sumitomo Dainippon Pharma Co Ltd, Subsidiaries
  • Sumitomo Dainippon Pharma Co Ltd, Key Competitors
  • Sumitomo Dainippon Pharma Co Ltd, Ratios based on current share price
  • Sumitomo Dainippon Pharma Co Ltd, Annual Ratios
  • Sumitomo Dainippon Pharma Co Ltd, Interim Ratios
  • Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Sumitomo Dainippon Pharma Co Ltd, Performance Chart (2017 - 2021)
  • Sumitomo Dainippon Pharma Co Ltd, Ratio Charts
  • Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Chugai Pharmaceutical Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Astellas Pharma Inc
  • Mitsubishi Tanabe Pharma Corp
  • Tsumura & Co
  • Nippon Shinyaku Co Ltd
  • Shin Nippon Biomedical Laboratories Ltd
  • Towa Pharmaceutical Co Ltd
  • Torii Pharmaceutical Co Ltd